摘要
背景与目的目前临床上对绝大多数晚期非小细胞肺癌患者缺乏有效的治疗方法和药物,本研究应用吉西他滨和顺铂两药联合化疗,观察该方案的临床疗效和毒副作用。方法对60例Ⅲ期及Ⅳ期的非小细胞肺癌患者给予吉西他滨1200mg/m2,第1、8天静脉输注;顺铂100mg/m2,第1天静脉输注或30mg/m2,第1、8天静脉输注。28天为一个周期,每例患者至少治疗2周期。结果全组完全缓解3例,部分缓解25例,无变化22例,进展10例,总有效率为46.67%。初治有效率为57.14%,复治为22.22%,差异有显著性(P<0.05)。毒性反应为白细胞减少和血小板减少,未影响到化疗的进行。结论吉西他滨联合顺铂治疗晚期非小细胞肺癌疗效较高,毒性可耐受。
Background and objective No chemotherapeutic regimen and agent are effective for most patients with advanced non-small cell lung cancer (NSCLC). This study is designed to evaluate the efficacy and toxicity of the combination of gemcitabine and cisplatin in the treatment of NSCLC. Methods Sixty cases of NSCLC in stage Ⅲ and Ⅳ were treated with gemcitabine 1200mg/m^2 by intravenous infusion on 1st and 8th days, and cisplatin 100mg/m^2 by intravenous infusion on 1st day or 30mg/m^2 by intravenous infusion on 1st and 8th days in a 28-day cycle. Each patient was treated at least for 2 cycles. Results An objective response was obtained in 46.67% of patients (3 complete and 25 partial responses), whereas 22 patients had no change and 10 patients were progressive. The response rate was 57.14% in patients without prior chemotherapy and 22.22% in patients with prior treatment. Significant difference existed between the two groups (P<0.05). The main toxicities were leukopenia and thrombocytopenia, but didn’t influence the chemotherapy. Conclusion The combination of gemcitabine and cisplatin is a feasible, well-tolerated and effective scheme in the treatment of advanced NSCLC.
出处
《中国肺癌杂志》
CAS
2005年第3期230-232,共3页
Chinese Journal of Lung Cancer
关键词
非小细胞肺癌
药物疗法
吉西他滨
顺铂
Non-small cell lung cancer Chemotherapy Gemcitabine Cisplatin
